SCYXHealthcare · Drug Manufacturers - Specialty & GenericSCYX Stock Forecast: SCYNEXIS, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering SCYNEXIS, Inc. hold a median 12-month price target of $33 — +527.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 22 Aug 2026 — in the lower half.
SCYX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores SCYNEXIS, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Value (11): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
SCYX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SCYX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +527.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Guggenheim | Maintains | Buy | $24 → $33 |
| 28 Oct 2025 | Guggenheim | Maintains | Buy | $4.00 → $3.00 |
| 28 Oct 2025 | Guggenheim | Maintains | Buy | — |
| 1 Apr 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 15 Aug 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 3 Apr 2023 | Guggenheim | Maintains | Buy | — |
| 3 Apr 2023 | Ladenburg Thalmann | Reiterates | Buy | — |
| 1 Mar 2023 | Guggenheim | Initiates | Buy | — |
| 21 Oct 2022 | Brookline Capital | Assumes | Buy | $8.00 |
| 13 May 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Mar 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 June 2021 | Aegis Capital | Maintains | Buy | — |
| 12 Apr 2021 | Aegis Capital | Maintains | Buy | — |
| 22 Jan 2021 | Guggenheim | Initiates | Buy | — |
| 6 Jan 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 28 Dec 2020 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2020 | Aegis Capital | Maintains | Buy | — |
| 25 Nov 2020 | Brean Capital | Initiates | Buy | — |
| 25 Nov 2020 | Canaccord Genuity | Initiates | Buy | — |
| 25 Nov 2020 | Guggenheim | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SCYX appears on the weeks it earns a place.
SCYX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, SCYNEXIS, Inc. returned −19.4% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SCYX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
SCYNEXIS, Inc. (SCYX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.9×
- Price / sales
- 2.6×
- Price / book
- 0.8×
- EV / EBITDA
- 0.1×
Cheaper than 71% of US stocks
Cheaper than 46% of US stocks
Cheaper than 80% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- −82.8%
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- −3308.5%
- Net margin
- −53.3%
Higher than 3% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 10% of US stocks
- Return on equity
- −18.4%
- Return on assets
- −20.8%
- Dividend yield
- —
Higher than 32% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SCYNEXIS, Inc. (SCYX) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
SCYNEXIS, Inc. has a market value of $50.7M and an enterprise value of −$1.4M.
Revenue in the twelve months to 31 Mar 2026: $20.3M. The latest quarter shrank 82.8% year on year.
Net income over the same four quarters: −$24.5M, a −120.5% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$5.9M.
Trailing P/E: 0.9×; forward P/E: −2.2× — the forward figure prices analyst consensus estimates, not reported earnings.
SCYNEXIS, Inc. employs 18 people — $1.1M of revenue per employee.
Data provided by Twelve Data
SCYX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own SCYNEXIS, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about SCYX stock
What is the SCYX stock price forecast for 2026-2027?
The 3 Wall Street analysts covering SCYNEXIS, Inc. have a median 12-month price target of $33, with estimates ranging from $32 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SCYX stock a buy right now?
Of the 3 analysts covering SCYNEXIS, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SCYNEXIS, Inc. 43 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SCYX?
As at 22 Aug 2026, SCYNEXIS, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
Will SCYX stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +527.4% from the last close, and Ticker Nerd's factor model ranks SCYNEXIS, Inc. 43 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SCYX stock forecast for 2030?
No analyst covering SCYNEXIS, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $45 over the next 12 months.
How has SCYX stock performed over the past year?
SCYNEXIS, Inc. returned -19.4% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does SCYNEXIS, Inc. do?
SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing therapies for difficult-to-treat fungal infections.
About SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing therapies for difficult-to-treat fungal infections. Its current portfolio centers on antifungal medicines designed to address conditions such as vulvovaginal candidiasis, recurrent vulvovaginal candidiasis, invasive candidiasis, and other serious invasive fungal diseases. The company’s marketed product, BREXAFEMME, is used in women’s health and infectious disease settings, while its research pipeline includes additional antifungal candidates such as SCY-247 aimed at broader systemic infections. SCYNEXIS’s work is concentrated on novel triterpenoid-based antifungal science, positioning it within the specialized anti-infective segment of the pharmaceutical market. Headquartered in Jersey City, New Jersey, SCYNEXIS serves a niche but important role in addressing infections where existing treatment options can be limited by resistance, tolerability, or disease severity.
CEO Dr. David Gonzalez Angulo M.D. · 18 employees · United States · https://www.scynexis.com